NYSE$DNA
Ginkgo Bioworks Holdings · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Ginkgo Bioworks reported a decrease in total revenue due to the expected ramp down of K-12 testing in Biosecurity, but saw an increase in Cell Engineering revenue. They ended the quarter with a strong cash position.
Ginkgo Bioworks reported a total revenue of $81 million for Q1 2023, a 52% decrease compared to the previous year. This decline was primarily due to the expected reduction in K-12 testing within the Biosecurity business. However, Cell Engineering revenue increased by 59% year-over-year, reaching $34 million. The company's cash and cash equivalents balance remained strong at approximately $1.2 billion.
- Added 13 new Cell Programs to the Foundry platform in Q1 2023, representing 18% growth over the prior year period
- Concentric generated $47 million in Biosecurity revenue.
- Acquired the AAV engineering platform assets of StrideBio.
- Ended Q1 2023 with approximately $1.2 billion in cash and cash equivalents.
Headline financials
Revenue & EPS history
Ginkgo Bioworks · Revenue · Quarterly
$80.7M
Forward guidance
Ginkgo expects to add 100 new Cell Programs and anticipates total revenue of at least $275 million in 2023.
Tailwinds
- Expects to add 100 new Cell Programs to the Foundry platform in 2023
- Expects Total revenue of at least $275 million in 2023
- Expects Cell Engineering revenue of at least $175 million in 2023
- Expects Biosecurity revenue in 2023 of at least $100 million
- Biosecurity revenue includes a mix shift towards emerging product lines that are expected to be more recurring in nature
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
-2.5%
Avg return
Earnings day
-8.6%
Avg return
5 days after
-12.3%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+25.4%
Q4 2021
Best reaction
-20.8%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.9% | -17.5% | -19.4% | |
| Q4 2025 | +3.1% | -28.6% | -36.8% | |
| Q3 2025 | -20.8% | -26.0% | -18.1% | |
| Q1 2025 | +14.8% | +28.8% | +17.7% | |
| Q4 2024 | -11.5% | -22.2% | -40.5% | |
| Q3 2024 | -1.8% | -27.3% | +17.9% | |
| Q2 2024 | -1.5% | +2.6% | -48.4% | |
| Q1 2024 | -14.8% | -3.4% | -42.4% | |
| Q4 2023 | -15.1% | -24.3% | -23.7% | |
| Q3 2023 | -18.2% | -16.9% | -11.7% | |
| Q2 2023 | -15.9% | -13.9% | +0.0% | |
| Q1 2023 | -2.9% | -3.6% | +35.0% | |
| Q4 2022 | -4.8% | -7.5% | -9.5% | |
| Q3 2022 | -6.3% | -23.2% | -41.1% | |
| Q2 2022 | +3.0% | -21.5% | -15.4% | |
| Q1 2022 | +3.0% | -1.9% | -2.6% | |
| Q4 2021 | +25.4% | +14.8% | -6.3% | |
| Q4 2019 | -0.3% | -0.5% | -11.8% | |
| Q3 2021 | +8.5% | +4.3% | -15.9% | |
| Q2 2021 | -0.1% | -0.3% | +1.5% | |
| Q1 2021 | +0.0% | -0.2% | +0.2% | |
| Q4 2020 | +0.0% | -0.2% | +0.2% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro